MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards
1.11.2024 13:37:00 CET | Business Wire | Press release
Palace fans can now download the MyGuava App and order a custom- designed Crystal Palace Card.Cards will provide users with cashback on all purchases, with up to 7% available for limited edition cards at any sporting goods store.900 ‘Palace Gold’ cards will also be made available, with each card providing the user with enhanced cashback and exclusive club benefits.
MyGuava in association with Crystal Palace Football Club is thrilled to launch exclusive Crystal Palace Fan Cards with rewards and a variety of perks as well as a unique opportunity for fans to celebrate their connection to the club while enjoying MyGuava’s seamless payment solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101068560/en/
MyGuava and Crystal Palace Launch Exciting Fan Payment Cards and Rewards (Photo: Business Wire)
Palace fans can now download the MyGuava App and order a Crystal Palace Card, choosing from three custom-designed cards: ‘Palace Gold’, ‘Palace Sash’ and ‘Selhurst 100’.
Each card comes packed with perks, including entry into exclusive prize draws, cashback on all purchases, giving Palace fans an opportunity to take advantage of the 7% cashback offer ahead of the festive period. Additionally, the cards come with Visa Platinum status for added financial flexibility.
Furthermore, for the most dedicated Eagles supporters, 900 limited-edition ‘Palace Gold’ cards will be available on a first come first served basis, offering enhanced cashback rates and special access to exclusive club benefits.
Rewards System
The MyGuava and Crystal Palace card will also be introducing a multi-stage reward system, providing cardholders with the exciting chance to earn Crystal Palace merchandise and experience based on spending. Supporters can win Crystal Palace branded bottles, t-shirts, hoodies as well as stadium tours and even personalised messages from the team for completing transaction milestones.
The MyGuava App, which is the flagship product of Guavapay, is designed to meet the broad financial needs of users. Users can open accounts in 20 currencies, make seamless local and global transfers, and use both virtual and physical debit cards. The App also has significant global reach, with access to 140 countries in more than 90 currencies and there are additional benefits with discounted gift cards from top brands and tools for enhancing user experience, such as digital skins, spending management tools and vaults.
To learn more about the Crystal Palace Card and Reward scheme, please visit the link below:
https://myguava.com/personal/landings/crystalpalace-cobrand-card
About Guavapay
Guavapay is a global fintech company with headquarters in London. The company has built a global financial ecosystem to empower individuals and businesses and give them more control over their financial lives. The All Things Payments App, MyGuava and the B2B platform, MyGuava Business simplify financial services, making them more accessible and affordable for people who have historically been overlooked.
The MyGuava Application is owned and operated by Guavapay Limited, a company registered in England with company number 10601900 and its registered address at Salisbury House, 29 Finsbury Circus, London, EC2M 5QQ, United Kingdom. Guavapay Limited is registered with the Financial Conduct Authority in the United Kingdom as a Small Electronic Money Institution with reference number 900888. Guavapay Limited’s ICO registration number is ZA274504.
For more information, please visit www.guavapay.com or contact:
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101068560/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom